Gelonghui, March 28, 丨 Yongtai Bio-B (06978.HK) announced that for the year ended December 31, 2023, the company's other revenue increased by about RMB 1.4 million or about 15.4% from about RMB 9.1 million in the previous year to about RMB 10.5 million. R&D expenditure increased by approximately RMB 1.1 million, or approximately 0.6%, from approximately RMB 176.2 million in the previous year to approximately RMB 177.3 million in the same year.

Total loss and overall expenses during the year increased by approximately RMB 14.4 million, or approximately 4.5%, from approximately RMB 321.1 million for the year ended 31 December 2022 to approximately RMB 335.5 million for the year ended 31 December 2023.